Program
retatrutide
Also written as “Retatrutide”, “LY3437943” and “Retatrutide (LY3437943)”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Atherosclerosis · Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, led by 2 companies.
Drug pageRetatrutide: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 3210 open or running | phase 3since May 22, 2023 | Feb 13, 2019 | Nov 2026phase 3 · NCT06662383 |
| Hudson Biotechits history only | 11 open or running | phase 2since Mar 8, 2026 | Mar 8, 2026 | Mar 14, 2027phase 2 · NCT07467447 |
- Named in Eli Lilly’s own pipeline as
Retatrutide
, phase 3, as of Oct 29, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 16 earlier studies, Feb 13, 2019 to Jul 17, 2023.
- Jan 19, 2023Named retatrutideINNProposed as its International Nonproprietary Name in WHO's List 128 · before, LY3437943
- Aug 16, 2023Phase 1 study in HealthyNCT06003465 · 57 enrolled · United States
- Sep 11, 2023Phase 1 study in OverweightNCT06039826 · 46 enrolled · United States
- Feb 8, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06260722 · 1,250 enrolled · United States, Argentina, Canada and more
- Mar 1, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06297603 · 341 enrolled · United States, Argentina, Brazil and more
- Mar 11, 2024Phase 1 study in ObesityNCT06313528 · 85 enrolled · United States
- Apr 3, 20242 phase 3 studiesNCT06354660, NCT06383390
- Oct 25, 2024Phase 3 study in ObesityNCT06662383 · 800 enrolled · United States, Argentina, Germany and more
- Jan 31, 2025Phase 1 study in HealthyNCT06808802 · 30 enrolled · Singapore
- Feb 28, 2025Phase 3 study in ObesityNCT06859268 · 643 enrolled · United States, Canada, United Kingdom
- May 14, 20252 phase 1 studiesNCT06982859, NCT06982846
- May 28, 2025Phase 3 study in ObesityNCT07035093 · 586 enrolled · United States, Argentina, Canada and more
- Aug 28, 2025Phase 3 study in Non-alcoholic Fatty Liver DiseaseNCT07165028 · 4,500 planned · United States, Argentina, Australia and more
- Nov 14, 2025Phase 3 study in ObesityNCT07232719 · 250 enrolled · United States, United Kingdom
- Jan 16, 2026Phase 3 study in ObesityNCT07357415 · 600 enrolled · United States, Argentina, Canada
Ahead
- Nov 2026Primary completion: phase 3 study in ObesityNCT06662383
- Jan 2027Primary completion: phase 1 study in Diabetes MellitusNCT06982859
- Jun 2027Primary completion: phase 3 study in ObesityNCT07232719
- Sep 2027Primary completion: phase 3 study in ObesityNCT07035093
TargetBeta
“Glucagon receptor agonist; Glucagon-like peptide 1 receptor agonist; Gastric inhibitory polypeptide receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
Studies
All 32 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07357415Obesity · United States, Argentina, Canada | 3 | Active, not recruiting | Oct 2028 | 600 |
| NCT07232719Obesity · United States, United Kingdom | 3 | Active, not recruiting | Jun 2027 | 250 |
| NCT07165028Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Recruiting | Aug 2030 | 4,500 |
| NCT07035093Obesity · United States, Argentina, Canada and more | 3 | Active, not recruiting | Sep 2027 | 586 |
| NCT06982859Diabetes Mellitus · Germany | 1 | Active, not recruiting | Jan 2027 | 95 |
| NCT06982846Diabetes Mellitus, Type 2 · Austria | 1 | Completed | May 4, 2026 | 80 |
| NCT06859268Obesity · United States, Canada, United Kingdom | 3 | Active, not recruiting | Apr 2028 | 643 |
| NCT06808802Healthy · Singapore | 1 | Completed | Apr 15, 2025 | 30 |
| NCT06662383Obesity · United States, Argentina, Germany and more | 3 | Active, not recruiting | Nov 2026 | 800 |
| NCT06383390Atherosclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 2029 | 10,000 |
| NCT06354660Diabetes Mellitus, Type 2 · United States, India, Mexico and more | 3 | Completed | Jan 22, 2026 | 537 |
| NCT06313528Obesity · United States | 1 | Completed | Aug 26, 2025 | 85 |
| NCT06297603Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Oct 26, 2026 | 341 |
| NCT06260722Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more | 3 | Active, not recruiting | Aug 27, 2026 | 1,250 |
| NCT06039826Overweight · United States | 1 | Completed | Jul 11, 2024 | 46 |
| NCT06003465Healthy · United States | 1 | Completed | Feb 8, 2024 | 57 |
| NCT05959096Healthy · United States | 1 | Completed | Jul 25, 2024 | 85 |
| NCT05936151Overweight · United States, Canada, Italy and more | 2 | Completed | Oct 1, 2025 | 146 |
| NCT05931367Obesity · United States, Australia, Canada and more | 3 | Completed | Nov 14, 2025 | 445 |
| NCT05929079Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | Jun 16, 2026 | 1,152 |
| NCT05929066Obesity · United States, Australia, Brazil and more | 3 | Completed | Apr 6, 2026 | 2,335 |
| NCT05916560Hepatic Insufficiency · United States | 1 | Completed | Mar 2, 2025 | 43 |
| NCT05882045Obesity · United States, Argentina, Australia and more | 3 | Completed | Apr 16, 2026 | 1,946 |
| NCT05757531Healthy · United States | 1 | Completed | Jun 23, 2023 | 7 |
| NCT05611957Renal Insufficiency · United States | 1 | Completed | Sep 5, 2023 | 29 |
| NCT05548231Overweight · China | 1 | Completed | Jul 27, 2023 | 32 |
| NCT05445232Obesity · United States | 1 | Completed | Feb 24, 2023 | 32 |
| NCT04881760Obesity · United States, Puerto Rico | 2 | Completed | May 16, 2022 | 338 |
| NCT04867785Diabetes Mellitus, Type 2 · United States, Puerto Rico | 2 | Completed | Jul 8, 2022 | 281 |
| NCT04823208Diabetes Mellitus, Type 2 · Japan | 1 | Completed | Jun 23, 2022 | 64 |
| NCT04143802Diabetes Mellitus, Type 2 · United States | 1 | Completed | Dec 28, 2020 | 72 |
| NCT03841630Healthy · Singapore | 1 | Completed | Jul 25, 2019 | 45 |
How it is read
Names in the registry
- “Retatrutide”, 18 entries
- “LY3437943”, 14 entries
- “Retatrutide (LY3437943)”, 1 entry
- “[¹⁴C]-LY3437943”, 1 entry
Conditions, from the studies’ own filings
- Obesity, 14 studies
- Diabetes Mellitus, Type 2, 8 studies
- Atherosclerosis, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.